News
-
-
COMMUNIQUÉ DE PRESSE
DEFENCE RECEIVES NO OBJECTION LETTER FROM HEALTH CANADA FOR PHASE I TRIAL OF ITS ACCUM-002 (ACCUTOX) AS AN ANTI-CANCER MOLECULE IN PATIENTS WITH MELANOMA
Defence Therapeutics Inc. receives Health Canada's No Objection Letter for Phase I trial of ACCUM-002 as anti-cancer drug in melanoma patients. The study aims to assess safety, tolerability, and efficacy of the drug -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
DEFENCE’S ARM-X ANTI-CANCER VACCINE INHIBITS GROWTH OF PRE-ESTABLISHED OVARIAN CANCER RESULTING IN COMPLETE RESPONSES IN TREATED ANIMALS
Defence Therapeutics Inc. announces successful inhibition of ovarian cancer growth with ARM-X anti-cancer vaccine and anti-PD-1 combination therapy in pre-established cancer models -
-
